Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) · 2025
The effect of chromium supplementation on cardio-metabolic risk factors in overweight and obese patients. A systematic review and meta-analysis of randomized controlled trial.
СтатьяМетаанализСистематический обзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Monfared Vahid, Rashin Hadiseh, Malekinejad Sara, Sheikhi Leila, Yousefi Mahsa, Vakili Mohammad Ali, Hasani Motahareh
Аннотация
OBJECTIVE: This study was conducted with the aim of evaluating the effect of chromium supplementation on cardiovascular-metabolic risk factors including lipid profile, glycemic index, anthropometric factors, blood pressure and liver function.
METHODS: Relevant studies were identified through electronic database searches (PubMed, Scopus, Web of Science) up to March 2024. The overall effect size was calculated using the mean changes and standard deviations for the intervention and control groups. The I2 statistic and Cochran's Q-test were used to determine the existence of heterogeneity. A non-linear modeling explored heterogeneity, dose-response relationships, and the overall impact of Chromium supplementation.
RESULTS: Twenty trials, with interventions ranging from 1 to 137 participant were included. Chromium supplementation significantly reduced Fasting blood glucose (FBG) ([WMD]: -1.60 mg/dl; 95 % [CI]: -3.28, 0.07; p = 0.06) and A1C ([WMD]: -0.05 %; 95 % [CI]: -0.19, 0.07; p = 0.38) HOMO-IR ([WMD]: -0.26; 95 % [CI]: 0.48, -0.03; p = 0.02) and insulin ([WMD]: -12.55 pmol/l; 95 % [CI]: -23.62, -1.47; p = 0.02) and a slight decrease in lipid profiles and anthropometric measures. However, there were some factors that Chromium was slightly increased compared to other groups, including: HDL, ALT, Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). Chromium has no significant effect on AST.
CONCLUSION: The results of this experiment show that chromium supplementation had a positive effect on blood sugar control and various factors including weight, BMI, SBP, DBP, triglycerides, and waist circumference, and had an effective role in improving the level of liver enzymes.
METHODS: Relevant studies were identified through electronic database searches (PubMed, Scopus, Web of Science) up to March 2024. The overall effect size was calculated using the mean changes and standard deviations for the intervention and control groups. The I2 statistic and Cochran's Q-test were used to determine the existence of heterogeneity. A non-linear modeling explored heterogeneity, dose-response relationships, and the overall impact of Chromium supplementation.
RESULTS: Twenty trials, with interventions ranging from 1 to 137 participant were included. Chromium supplementation significantly reduced Fasting blood glucose (FBG) ([WMD]: -1.60 mg/dl; 95 % [CI]: -3.28, 0.07; p = 0.06) and A1C ([WMD]: -0.05 %; 95 % [CI]: -0.19, 0.07; p = 0.38) HOMO-IR ([WMD]: -0.26; 95 % [CI]: 0.48, -0.03; p = 0.02) and insulin ([WMD]: -12.55 pmol/l; 95 % [CI]: -23.62, -1.47; p = 0.02) and a slight decrease in lipid profiles and anthropometric measures. However, there were some factors that Chromium was slightly increased compared to other groups, including: HDL, ALT, Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP). Chromium has no significant effect on AST.
CONCLUSION: The results of this experiment show that chromium supplementation had a positive effect on blood sugar control and various factors including weight, BMI, SBP, DBP, triglycerides, and waist circumference, and had an effective role in improving the level of liver enzymes.